

It is illegal to post this copyrighted PDF on any website.

# Does Half-Life Matter After Antipsychotic Discontinuation?

## A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone

Peter J. Weiden, MD<sup>a,e</sup>; Edward Kim, MD, MBA<sup>b,\*</sup>; Jason Bermak, MD, PhD<sup>c</sup>; Ibrahim Turkoz, PhD<sup>d</sup>; Srihari Gopal, MD<sup>d</sup>; and Joris Berwaerts, MD<sup>d</sup>

### ABSTRACT

**Objective:** To evaluate the effect of 1 oral and 2 distinct long-acting injectable (LAI) formulations of the same antipsychotic on times to relapse following medication discontinuation.

**Methods:** Data were drawn from 3 similarly designed, multicenter, double-blind, placebo-controlled, randomized-withdrawal studies of paliperidone in adults with a schizophrenia diagnosis (according to *DSM-IV* criteria for  $\geq 1$  year before screening): once-daily extended-release oral paliperidone (ORAL paliperidone), once-monthly paliperidone palmitate (PP1M), and once-every-3-months paliperidone palmitate (PP3M). In a post hoc analysis, we compared median time to relapse across the treatment-withdrawal arms of the 3 studies using final analysis datasets. Time to relapse in the withdrawal arm of each study was examined using log-rank tests and Cox proportional hazards models.

**Results:** Four hundred forty-nine patients were withdrawn from 3 paliperidone formulations: 101 from ORAL paliperidone, 203 from PP1M, and 145 from PP3M. Postwithdrawal median (95% confidence interval [CI]) days to relapse were 58 days (42–114 days) for ORAL paliperidone, 172 days (134–222 days) for PP1M, and 395 days (274 days–not reached) for PP3M ( $P < .0001$ , pairwise comparisons). Relapse risk was significantly lower ( $P < .001$ ) for patients who withdrew from either PP formulation relative to ORAL paliperidone and additionally for patients who withdrew from PP3M relative to PP1M.

**Conclusions:** Results demonstrate that 50% of patients who withdrew treatment from ORAL paliperidone, PP1M, or PP3M remained relapse free for approximately 2 months, 6 months, and 13 months, respectively. This may be relevant for risk mitigation strategies in schizophrenia, a condition in which interruptions in maintenance antipsychotic treatment are commonplace and unpredictable. LAI antipsychotic formulations may provide substantial delays over oral equivalents in times to relapse when patients discontinue therapy.

**Trial Registration:** ClinicalTrials.gov identifiers: NCT00086320, NCT00111189, and NCT01529515

*J Clin Psychiatry* 2017;78(7):e813–e820

<https://doi.org/10.4088/JCP.16m11308>

© Copyright 2017 Physicians Postgraduate Press, Inc.

<sup>a</sup>Uptown Research Institute, LLC, Chicago, Illinois

<sup>b</sup>Janssen Scientific Affairs, LLC, Titusville, New Jersey

<sup>c</sup>SF-CARE, Inc, San Rafael, California

<sup>d</sup>Janssen Research and Development, Titusville, New Jersey

<sup>e</sup>Dr Weiden is now an employee of Alkermes, Inc, Waltham, Massachusetts

\*Corresponding author: Edward Kim, MD, MBA, Therapeutic Area Leader, Schizophrenia, Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Rd, Room A32405, Titusville, NJ 08560 (ekim37@its.jnj.com).

Preventing or delaying relapse is a major goal in the treatment of schizophrenia.<sup>1,2</sup> Relapse is at best disruptive<sup>2</sup>; at worst, it can be lethal.<sup>3</sup> Studies show that relapse has a multitude of negative consequences to a person's physiologic, psychological, and social well-being.<sup>1–3</sup> Ideally, patients with schizophrenia should receive continuous antipsychotic maintenance therapy, an approach widely recognized as an important strategy for delaying relapse.<sup>4–7</sup> When this is not possible, symptom-targeted and intermittent antipsychotic administration strategies have been used, but are associated with unacceptable increases in relapse risk and are therefore not recommended.<sup>8,9</sup> Psychosocial approaches to reduce relapse risk include educating patients and their caregivers about the early warning signs of relapse, maintaining open lines of communication between the patient and clinical care team, and establishing advance directives.<sup>2,10–12</sup> Antipsychotic formulations with longer half-lives may potentially delay relapse by providing continuous exposure well beyond the point of medication discontinuation.<sup>9,13–18</sup>

While the premise that relapse may be delayed longer after discontinuing a long-acting injectable (LAI) formulation than after discontinuing its oral formulation seems intuitive, no study has examined, to our knowledge, the relationship between the half-lives of antipsychotic formulations and time to relapse following discontinuation.

The antipsychotic paliperidone is available as once-daily extended-release oral paliperidone (ORAL paliperidone),<sup>19</sup> once-monthly LAI paliperidone palmitate (PP1M),<sup>15</sup> and once-every-3-months LAI paliperidone palmitate (PP3M).<sup>20</sup> The same pharmacodynamic properties of paliperidone apply across the 3 formulations, but their pharmacokinetics differ.<sup>15,19,20</sup> Following single-dose administration of ORAL paliperidone, paliperidone concentrations gradually rise to reach peak plasma concentrations approximately 24 hours postdose.<sup>19</sup> The half-life of ORAL paliperidone is approximately 23 hours.<sup>19</sup> Due to their extremely low solubility in water, PP1M and PP3M dissolve slowly after intramuscular injection before being hydrolyzed to paliperidone and absorbed into the systemic circulation.<sup>15,20</sup> Therefore, the apparent (observed) elimination half-lives of PP1M and PP3M are based on their slow release from the muscle. Paliperidone release starts as early as day 1, peaks at day 13 (PP1M) or day 30 to 33 (PP3M), and is detectable for up to 126 days (PP1M) or 18 months (PP3M).<sup>15,20</sup> The

You are prohibited from making this PDF publicly available.

- Long-acting injectable (LAI) antipsychotic formulations may provide substantial benefits over oral equivalents in times to relapse when patients discontinue therapy.
- The LAI with the longest known half-life, once-every-3-months paliperidone palmitate, confers the most enduring relapse prevention and may represent a buffer against medication interruptions, providing clinicians and caregivers with an extended opportunity to ensure continued follow-up and treatment continuity.

median apparent half-life of paliperidone following single-dose administration of PP1M over a 39-mg to 234-mg range is 25 to 49 days.<sup>15</sup> The median apparent half-life of paliperidone following PP3M administration over a 273-mg to 819-mg range is 84 to 95 days and 118 to 139 days following deltoid and gluteal injections, respectively.<sup>20</sup>

Each of the 3 paliperidone formulations has been assessed for safety and efficacy in its own long-term, double-blind, randomized withdrawal study.<sup>21–23</sup> In these studies, relapse was defined as 1 or more of the following: psychiatric hospitalization for schizophrenia symptoms; a predefined increase in the Positive and Negative Syndrome Scale (PANSS) total score<sup>24</sup> for 2 consecutive assessments; an increase in prespecified individual PANSS item scores for 2 consecutive assessments; clinically significant deliberate self-injury or violent behavior resulting in suicide, injury, or significant damage; or suicidal or homicidal ideation and aggressive behavior.<sup>21–23</sup> The protocols and patient populations of each study were nearly identical, including similar inclusion and exclusion criteria, stabilization criteria, and relapse criteria.<sup>21–23</sup> Therefore, time to relapse data from the antipsychotic withdrawal group of each study could be used to evaluate whether differences in apparent half-lives provide clinically meaningful differences in time to relapse. We tested the hypothesis that patients who discontinue 1 of the long-acting formulations of paliperidone (PP1M or PP3M) will have a longer delay to relapse than those who discontinue the oral paliperidone formulation (ORAL paliperidone), and the duration of this delay will be proportional to length of half-life, with PP3M providing a longer delay than PP1M. We explored this hypothesis by conducting a post hoc exploratory analysis that compared times to first relapse in adults with schizophrenia after double-blind discontinuation from ORAL paliperidone, PP1M, or PP3M.

## METHODS

Analysis groups consisted of subjects who successfully completed the open-label stabilization phase of each study and were randomized to the placebo arm (and were therefore withdrawn from 1 of the 3 paliperidone formulations) for the double-blind relapse-prevention phase. Patients in each of the 3 placebo arms would have had therapeutic levels of paliperidone until randomized withdrawal.

## Designs of the 3 Trials

This analysis used data from similarly designed, randomized, double-blind, placebo-controlled, relapse-prevention studies with ORAL paliperidone,<sup>21</sup> PP1M,<sup>22</sup> and PP3M.<sup>23</sup> Each was a manufacturer-sponsored registration trial to support the long-term use of each formulation.<sup>21–23</sup> Collectively, the studies spanned 10 years, with the ORAL paliperidone study conducted from 2004 to 2005, PP1M from 2005 to 2007, and PP3M from 2012 to 2014.<sup>21–23</sup> Each study was approved by the local ethics committee, written informed consent was obtained, and the studies were registered at ClinicalTrials.gov (identifiers: NCT00086320, NCT00111189, and NCT01529515, respectively).

Shared elements of the overall study design and modifications and differences are shown in Figure 1. Each study had a screening phase, after which patients entered an open-label stabilization period ranging from 8 to 17 weeks (8 weeks for ORAL paliperidone, 9 weeks for PP1M, and 17 weeks for PP3M). Detailed information about the range of paliperidone dosing regimens used for each of the studies is described in Supplementary eTables 1–3 of eAppendix 1.

Stabilization criteria in each paliperidone study consisted of establishing a stable study drug dose with acute-symptom control, defined as a PANSS total score below a predetermined threshold ( $\leq 70$  for the ORAL paliperidone study,  $\leq 75$  for PP1M, and  $< 70$  for PP3M); PANSS scores of  $\leq 4$  (moderate or less) on selected individual items (P1 [delusions], P2 [conceptual disorganization], P3 [hallucinatory behavior], P6 [suspiciousness/persecution], P7 [hostility], G8 [uncooperativeness], and, for PP1M and PP3M only, G14 [poor impulse control]), in addition to a Clinical Global Impressions–Severity (CGI-S)<sup>25</sup> score of  $\leq 4$  (moderately ill or better) for ORAL paliperidone only.<sup>21–23</sup>


Patients who met stabilization criteria were randomly assigned to continue treatment with the active paliperidone medication or were withdrawn from active paliperidone to placebo under double-blind conditions, continuing the same dosage schedule used at the end of the respective stabilization phase (daily for ORAL paliperidone, every 4 weeks for PP1M, and every 12 weeks for PP3M). The interval between the last dose of antipsychotic medication and initiation of placebo after randomization was based on the normal dosing schedule for each formulation studied: 1 day for ORAL paliperidone, 1 month for PP1M, and 3 months for PP3M. Patients remained in the double-blind phase until they relapsed or withdrew from the study, or until the study was terminated.<sup>21–23</sup>

## Key Inclusion/Exclusion Criteria

Supplementary eTable 4 shows full inclusion and exclusion criteria for the 3 trials; Figure 1 presents the major criteria. Briefly, men and women aged 18–65 years ( $\leq 70$  years in the PP3M trial) were eligible if they had a schizophrenia diagnosis according to *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition (*DSM-IV*), criteria for  $\geq 1$  year before screening.<sup>21–23</sup> Original *DSM-IV* criteria were used in the ORAL paliperidone and PP1M studies,<sup>21,22</sup>

It is illegal to post this copyrighted PDF on any website.

Figure 1. Flowchart of the Overall Study Design, Highlighting Major Similarities and Differences Among the ORAL,<sup>21</sup> PP1M,<sup>22</sup> and PP3M<sup>23</sup> Studies



<sup>a</sup>The ORAL study also had additional criteria using predefined changes in Clinical Global Impressions–Severity score. The primary outcome criteria never detected any unique relapse events during this study, so the criteria were dropped for the later studies.

<sup>b</sup>One patient did not receive study drug and therefore was not included in this analysis.

Abbreviations: DB = double-blind; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; OL = open label; ORAL = daily extended-release oral paliperidone; PP1M = once-monthly long-acting injectable paliperidone palmitate; PP3M = once-every-3-months long-acting injectable paliperidone palmitate.

and DSM-IV Text Revision criteria were used in the PP3M study.<sup>23</sup> Criteria for a schizophrenia diagnosis were the same in the original DSM-IV and Text Revision editions. A total PANSS score < 120 at screening and baseline was another common criterion.<sup>21–23</sup>

All studies shared standard exclusion criteria such as DSM-IV diagnosis other than schizophrenia and other standard medical or psychiatric exclusion criteria (see eAppendix 1). There were some differences between studies in history of long-acting formulations. Patients were also excluded if they used a 4-week depot antipsychotic within 28 days (PP1M study)<sup>22</sup> or within 120 days (ORAL paliperidone


study)<sup>21</sup> of screening. In the PP3M study, symptomatically stable patients could transition from another LAI antipsychotic to PP1M before transitioning to PP3M if there was a clinical reason to switch medications.<sup>23</sup>

### Study End Points

The primary outcome measure for all studies was time until first schizophrenia relapse, as defined by Csernansky et al<sup>26</sup> (Figure 2). Patients were considered to have relapsed if they met 1 or more of the following: psychiatric hospitalization for schizophrenia symptoms; a predefined increase in the PANSS total score for 2 consecutive assessments; an

It is illegal to post this copyrighted PDF on any website.

Figure 2. Kaplan-Meier Plot of Time to Relapse for Patients in the Placebo Arms of ORAL,<sup>21</sup> PP1M,<sup>22</sup> and PP3M<sup>23</sup> Studies



increase in prespecified individual PANSS item scores for 2 consecutive assessments; clinically significant deliberate self-injury or violent behavior resulting in suicide, injury, or significant damage; or suicidal or homicidal ideation and aggressive behavior.<sup>21-23</sup>

Relevant secondary efficacy measures were changes from double-blind baseline to end point in the PANSS total and factor, CGI-S, and Personal and Social Performance (PSP) scale scores.<sup>21-23</sup> Safety measures and results for each study were reported previously<sup>21-23</sup> and were not included in the analysis.

During each study, an independent data-monitoring committee performed a preplanned interim analysis after a predefined number of relapse events (ORAL paliperidone, no. = 43; PP1M, no. = 68; and PP3M, no. = 42). The study was terminated early if efficacy was established at this interim analysis at a prespecified level of significance (.01, .0106, and .0101 for ORAL paliperidone, PP1M, and PP3M, respectively). A final analysis evaluating all events that occurred by study termination was conducted as a supporting analysis in each study.<sup>21-23</sup>

**Primary Outcome Measure for Post Hoc Analysis**

Time to first relapse after antipsychotic discontinuation was explored in the 3 cohorts of patients who were symptomatically

stable and received a paliperidone formulation during the open-label transition and maintenance phases. During the double-blind phase of their respective studies, active drug was discontinued and patients were assigned to placebo.

**Statistical Methods**

Each study was terminated early for efficacy following an interim analysis. Because the interim analysis demonstrated a statistically significant difference in favor of study drugs compared with placebo, with regard to the time to relapse, the independent data-monitoring committee recommended stopping the trial for efficacy in all 3 studies.

The final data analysis, which included data points subsequent to the interim analysis data cutoff and cumulative up to the date of study completion, was considered the final database use for this study. The double-blind intent-to-treat population, including all randomly assigned patients who received ≥ 1 dose of double-blind study drug, was used for this analysis. Only those patients randomly assigned to placebo were included. Demographic and baseline characteristics were summarized using descriptive statistics for the double-blind phase of each study and were compared using analysis of variance or  $\chi^2$  tests for continuous and categorical variables, respectively, to identify potential confounders.

You are prohibited from making this PDF publicly available.



It is illegal to post this copyrighted PDF on any website.

**Table 1. Time to Relapse and Reason for Relapse After Assignment to Placebo**

Variable	Placebo Arms		
	PP1M vs ORAL	PP3M vs ORAL	PP3M vs PP1M
Unadjusted HR (95% CI) <sup>a</sup>	0.441 (0.313–0.620)	0.212 (0.140–0.320)	0.480 (0.334–0.691)
<i>P</i> value	<.0001	<.0001	.0001
Time to relapse	ORAL Study (n = 101)	PP1M Study (n = 203)	PP3M Study (n = 145)
Events, no. (%)	52 (51.5)	97 (47.8)	42 (29.0)
K-M 25th percentile, days (95% CI)	23 (14–28)	71 (54–85)	141 (104–190)
K-M median, days (95% CI)	58 (42–114)	172 (134–222)	395 (274–NR)
Reason for relapse, n (%) <sup>b</sup>	ORAL Study (n = 205)	PP1M Study (n = 408)	PP3M Study (n = 305)
Psychiatric hospitalization	19 (9.3)	21 (5.2)	15 (4.9)
PANSS total score	60 (29.3)	117 (28.7)	45 (14.8)
Deliberate self-injury, violent behavior	2 (1.0)	5 (1.2)	5 (1.6)
Suicidal or homicidal ideation	4 (2.0)	6 (1.5)	5 (1.6)
CGI-S score	56 (27.3)	0 (0)	0 (0)
PANSS items (P1, P2, P3, P6, P7, G8)	29 (14.2)	36 (8.8)	8 (2.6)

<sup>a</sup>Hazard ratio and *P* values are from Cox proportional hazards model on time to relapse.  
<sup>b</sup>Patients could have more than 1 reason for relapse.  
Abbreviations: CGI-S = Clinical Global Impressions–Severity, CI = confidence interval, HR = hazard ratio, K-M = Kaplan-Meier, NR = not reached, ORAL = daily extended-release oral paliperidone, PANSS = Positive and Negative Syndrome Scale, PP1M = once-monthly long-acting injectable paliperidone palmitate, PP3M = once-every-3-months long-acting injectable paliperidone palmitate.

The cumulative distribution function of time to relapse was estimated using the Kaplan-Meier method, and time to relapse among studies was evaluated using a log-rank test. Differences in relapse risk among trials were evaluated using Cox proportional hazards models. Estimates of hazard ratios and 95% confidence intervals (CIs) among studies were provided. Patient characteristics that differed ( $P < .2$ ) between the groups at baseline were included as covariates in the analysis to increase statistical power and to examine the influence of these baseline differences on analysis results. The impact of baseline prognostic factors and parametric Cox regression models were evaluated using differences in log-likelihoods. Model fits and diagnostics were examined for violation of the assumption of proportional hazards, influential data points, and nonlinearity. Reasons for relapse were summarized. No adjustment was made for multiplicity.

## RESULTS

### Patient Characteristics

This post hoc analysis includes data from 101, 203, and 145 patients randomly assigned to the double-blind placebo arms of the ORAL paliperidone, PP1M, and PP3M studies, respectively. Baseline demographic and disease characteristics were generally well-balanced across studies (Supplementary eTable 5). Patients were predominantly white (60%–66%) with mean ages ranging from 37.5 to 39.4 years. In each group, schizophrenia diagnosis occurred in the mid-to-late 20s. As indicated by mean  $\pm$  SD total PANSS scores, symptom severity appeared comparable in the ORAL paliperidone ( $53.4 \pm 10.6$ ), PP1M ( $53.1 \pm 11.9$ ), and PP3M ( $54.2 \pm 9.3$ ) placebo arms at randomization ( $P = .642$ ) and was consistent with symptomatic stabilization.<sup>21–23</sup> Small but statistically significant differences were observed across arms for gender, race, mean baseline PSP scale scores, and

number of prior hospitalizations; these differences were not considered clinically meaningful.

Baseline demographics and clinical characteristics of all patients who entered the double-blind phase and were randomly assigned to placebo are shown in Supplementary eTable 6.

### Time to First Relapse After Initiation of Placebo

In the placebo arms of the respective studies, median time from double-blind baseline to relapse differed significantly in the final analysis set: 58 days (95% CI, 42–114 days) for ORAL paliperidone, 172 days (95% CI, 134–222 days) for PP1M, and 395 days (95% CI, 274 days–not reached) for PP3M ( $P < .0001$ , pairwise comparisons; Figure 2, Table 1). These data indicate that withdrawal from either PP1M or PP3M was associated with delayed time to relapse relative to that of ORAL paliperidone. Further comparison shows that patients in the PP3M withdrawal group remained stable for longer than those in the PP1M withdrawal group. Relapse risk was 56% lower for patients discontinuing PP1M than for those discontinuing ORAL paliperidone ( $P < .001$ ), 79% lower for patients discontinuing PP3M than for those discontinuing ORAL paliperidone ( $P < .001$ ), and 52% lower for patients discontinuing PP3M than for those discontinuing PP1M ( $P < .001$ ) (Figure 2, Table 1).

Sensitivity analyses and tests of model assumptions indicated that these results were robust. Baseline (prerandomization) PSP scores and number of prior hospitalizations for psychosis differentially affected risk of relapse (Table 2), indicating that these variables could potentially confound the interpretation of the data from time-to-event analysis for the overall study population. Cox proportional hazards models using these factors as covariates yielded similar results, further demonstrating the robustness of findings (Table 1, Table 2, and Supplementary eTable 7).

**Table 2. Sensitivity Analysis: Baseline Factors Influencing Risk of Relapse<sup>a</sup>**

Predictor	Maximum Likelihood Estimates				
	Estimate	SE	P Value	HR Estimates	
				Estimate	95% CI
Baseline (DB) PSP	-0.019	0.007	.012	0.982	0.967–0.996
Age at diagnosis of schizophrenia	-0.006	0.008	.434	0.994	0.978–1.010
Trial			<.001		
PP1M vs ORAL	-0.859	0.185	<.001	0.424	0.295–0.609
PP3M vs ORAL	-1.349	0.242	<.001	0.259	0.161–0.417
Prior hospitalizations for psychosis <sup>b</sup>			.394		
1 vs 0	0.418	0.262	.110	1.519	0.909–2.538
2 vs 0	0.271	0.286	.343	1.312	0.749–2.298
3 vs 0	0.424	0.312	.175	1.527	0.828–2.816
≥4 vs 0	0.519	0.279	.063	1.681	0.973–2.902
Race			.839		
Asian vs white	0.228	0.248	.358	1.256	0.772–2.043
Black/African American vs white	0.047	0.215	.828	1.048	0.688–1.596
Other vs white	0.033	0.357	.927	1.033	0.513–2.082
Sex, female vs male	0.191	0.160	.234	1.210	0.884–1.656

<sup>a</sup>Multiple Cox proportional hazards model on time to relapse for the placebo arms of the ORAL, PP1M, and PP3M trials (DB intent-to-treat populations) with these predictors: trials, race, sex, baseline (DB) PSP, age at diagnosis of schizophrenia (years), and prior hospitalizations for psychosis.

<sup>b</sup>For the PP3M cohort, this is the number of hospitalizations within 24 months before the start of the study. There was no defined time component for the ORAL or PP1M cohorts.

Abbreviations: CI = confidence interval, DB = double-blind, HR = hazard ratio, ORAL = daily extended-release oral paliperidone, PP1M = once-monthly long-acting injectable paliperidone palmitate, PP3M = once-every-3-months long-acting injectable paliperidone palmitate, PSP = Personal and Social Performance scale, SE = standard error.

Model fits and diagnostics were examined for violation of the assumption of proportional hazards, influential data points, and nonlinearity. Multicollinearity among the predictors was also assessed. The assumptions of constant hazard ratio among the groups were confirmed (Supplementary eTable 7, Supplementary eFigure 1).

### Reason for Relapse

Symptom exacerbation as reflected by increase in PANSS total score was the most common reason for relapse in each trial (Table 1). Increases in PANSS total scores were the main reason for relapse in 29.3%, 28.7%, and 14.8% of patients, respectively, in the ORAL paliperidone, PP1M, and PP3M studies. Other reasons for relapse varied across trials (Table 1).

### DISCUSSION

To our knowledge, this is the first analysis comparing the effects of 3 distinct LAI antipsychotic formulations on the risk and timing of relapse following antipsychotic discontinuation. This post hoc analysis, which included data from 3 similarly designed studies,<sup>21–23</sup> compared times to first relapse for adults with schizophrenia who were withdrawn to placebo after double-blind treatment with ORAL paliperidone, PP1M, or PP3M. Postwithdrawal median (95% CI) relapse times were 58 days (42–114 days) for ORAL paliperidone, 172 days (134–222 days) for PP1M, and 395 days (274 days–not reached) for PP3M.

Because individual patients may have different relapse trajectories, these times to relapse should be considered estimates rather than precise predictions. The relapse risk

(hazard ratio) was 2.27-fold higher for patients discontinuing ORAL paliperidone than for those discontinuing PP1M, 4.71-fold higher for patients discontinuing ORAL paliperidone than for those discontinuing PP3M, and 2.08-fold higher for patients discontinuing PP1M than for those discontinuing PP3M (Table 1). These relative risk reductions are conservative in that they assess only time since randomization to placebo in the double-blind phase and do not include time since the last dose of medication in the maintenance phase.

Our findings are consistent with the expectation that longer half-lives are associated with longer periods of relapse-free clinical stability following discontinuation. Both the PP1M and PP3M formulations were associated with a longer time to relapse than the oral formulation. These results are in agreement with interim analyses of the individual studies, in which median times from double-blind baseline to relapse were 62, 163, and 274 days, respectively, with ORAL paliperidone,<sup>21</sup> PP1M,<sup>22</sup> and PP3M.<sup>23</sup> Patients randomized to the PP3M placebo arm also had a longer median time to relapse than those randomized to the PP1M placebo arm, again consistent with the hypothesis that longer half-life is associated with longer time to relapse after discontinuation, even among LAI formulations.<sup>13</sup>

Presently, there is no established or consensus definition of relapse for schizophrenia. Historically, hospitalization was the hallmark of relapse,<sup>27,28</sup> but over the past 10 to 20 years, the definition of relapse has evolved. The definition of relapse used in the 3 randomized controlled paliperidone studies, which served as the basis for this post hoc analysis, was based on regulatory guidelines and is more rigorous than definitions used a few decades ago.<sup>21–23</sup> Relapse-prevention

**It is illegal to post this copyrighted PDF on any website.**

studies are now designed to detect early signs of impending relapse (eg, suicidal behavior and ideation, increased PANSS item scores), so that at-risk subjects are immediately discontinued from the study and optimal treatment interventions are instituted. Differences in the definition of relapse used in older studies preclude comparison to the present findings. A strength of our analysis is that all 3 paliperidone studies used the same definition of relapse, allowing the comparison of relapse data across studies.

Continuous exposure to antipsychotic medication is key to effective long-term schizophrenia treatment because it provides sustained symptom control and optimizes clinical and psychosocial outcomes.<sup>4,5,12,29</sup> Nevertheless, patients with schizophrenia often have difficulty maintaining consistent medication adherence,<sup>27,30–32</sup> increasing relapse risk and its negative consequences.<sup>27,32</sup> Given the prevalence and seriousness of relapse in schizophrenia, relapse risk mitigation may be of benefit when medication discontinuation cannot be prevented.<sup>2,12</sup> One risk-mitigation approach is asking patients to continue antipsychotic medication with a gradual down-titration schedule rather than abrupt medication discontinuation,<sup>2,33</sup> thereby enabling patients to retain medication as part of their treatment plan while still benefiting from a reduced dose and closely monitoring for emerging relapse. It also preserves the therapeutic relationship between health care provider and patient and provides immediate access to crisis services after medication cessation, making it easier for patients to seek help during early stages of relapse.<sup>2,11</sup> While a gradual dose reduction is possible with oral therapy, patients who decide to stop oral medication often do so without informing their treatment team. On the other

hand, those treated with LAIs will continue to have slowly diminishing levels of medication until they can be persuaded to resume antipsychotic therapy.

This analysis has several limitations. First, this was a post hoc analysis of data from 3 separate studies. Although the patient populations and study designs were nearly identical, the studies were not designed to assess time to relapse after withdrawal from active treatment. Second, although the studies had similar designs, they differed in the duration of paliperidone exposure during the open-label lead-in phases, length of follow-up during the double-blind phases, and timing of interim analyses. The stabilization phases were different lengths in the 3 studies and evaluated different equivalent dose ranges of paliperidone. Most notably, the range of PP1M doses evaluated was slightly lower than that of the other paliperidone formulations. However, sensitivity analyses controlling for observed relapse risk factors only modestly reduced the magnitude of differences observed in our primary analysis.

In conclusion, results of this post hoc analysis demonstrate that 50% of patients who withdrew treatment from ORAL paliperidone, PP1M, or PP3M remained relapse free for approximately 2 months, 6 months, and 13 months, respectively. This observation may be relevant for risk mitigation strategies in schizophrenia, a condition in which interruptions in maintenance antipsychotic treatment are commonplace and unpredictable. Of the 3 formulations evaluated, PP3M conferred the most enduring relapse prevention and may represent a buffer against medication interruptions, providing clinicians and caregivers with an extended opportunity to ensure continued follow-up and treatment continuity.

**Submitted:** October 27, 2016; accepted March 22, 2017.

**Online first:** June 20, 2017.

**Potential conflicts of interest:** At the time of this analysis, **Dr Weiden** was an employee of Uptown Research Institute, LLC, but is now a full-time employee of Alkermes, Inc. Prior to his employment with Alkermes, he was on the speaker bureaus of Alkermes, Forum, Janssen, Lundbeck, Otsuka, and Sunovion; was a consultant for Allergan, Alkermes, Delpor, Forum, Janssen, Lundbeck, Otsuka, Novartis, Sunovion, Teva, and Vanda; received research funding for clinical trials (as investigator or sub-investigator with Uptown Research Institute, LLC) from Allergan, Alkermes, Boehringer-Ingelheim, Forum, Intracellular, Janssen, Neurocrine, Otsuka, Reckitt Benckiser, and Takeda; and is a Delpor stockholder. His financial conflicts of interest had ended and his work on conceptualizing, writing, and revising this manuscript was completed prior to his employment with Alkermes (June 2016). **Dr Kim** is an employee of Janssen Scientific Affairs, LLC, and a Johnson & Johnson stockholder. **Dr Bermak** was a principal investigator on the R092670-PSY-3012 study (NCT01529515), and has received research funding for this and other Janssen clinical trials, and has received honoraria for his participation in the Janssen speaker bureau. **Drs Turkoz** and **Gopal** are employees of Janssen Research and Development, LLC, and are Johnson & Johnson stockholders. **Dr Berwaerts** is a former employee of Janssen Research and Development, LLC.

**Funding/support:** This study was funded by Janssen Scientific Affairs, LLC.

**Role of the sponsor:** This study was funded by Janssen Scientific Affairs, LLC, which was responsible for the design and conduct of the study; collection, management, analysis, and interpretation of data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. Writing and editorial assistance was also funded by Janssen Scientific Affairs, LLC.

**Acknowledgments:** The authors thank Matthew Grzywacz, PhD, Lynn Brown, PhD, and Marguerite York, PhD (ApotheCom, Yardley, Pennsylvania), for their writing and editorial assistance, which was funded by Janssen.

**Additional information:** Janssen makes its trial data available through the Yale Open Data Access (YODA) project. Requests can be made at: <http://yoda.yale.edu>.

**Supplementary material:** See accompanying pages.

## REFERENCES

1. Kane JM. Treatment strategies to prevent relapse and encourage remission. *J Clin Psychiatry*. 2007;68(suppl 14):27–30.
2. Kane JM. Improving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring success. *J Clin Psychiatry*. 2013;74(9):e18.
3. Kennedy JL, Altar CA, Taylor DL, et al. The social

and economic burden of treatment-resistant schizophrenia: a systematic literature review. *Int Clin Psychopharmacol*. 2014;29(2):63–76.

4. Kreyenbuhl J, Buchanan RW, Dickerson FB, et al; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. *Schizophr Bull*. 2010;36(1):94–103.
5. Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull*. 2010;36(1):71–93.
6. Schooler NR. Maintenance medication for schizophrenia: strategies for dose reduction. *Schizophr Bull*. 1991;17(2):311–324.
7. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. *Arch Gen Psychiatry*. 1997;54(5):453–463.
8. Wistedt B, Wiles D, Jørgensen A. A depot neuroleptic withdrawal study neurological effects. *Psychopharmacology (Berl)*. 1983;80(2):101–105.
9. De Hert M, Sermon J, Geerts P, et al. The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics. *CNS Drugs*.

It is illegal to post this copyrighted PDF on any website.

- 2015;29(8):637–658.
10. Hamann J, Mischo C, Langer B, et al. Physicians' and patients' involvement in relapse prevention with antipsychotics in schizophrenia. *Psychiatr Serv*. 2005;56(11):1448–1450.
  11. Sariah AE, Outwater AH, Malima KI. Risk and protective factors for relapse among individuals with schizophrenia: a qualitative study in Dar es Salaam, Tanzania. *BMC Psychiatry*. 2014;14:240.
  12. Kane JM, Leucht S, Carpenter D, et al; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. *J Clin Psychiatry*. 2003;64(suppl 12):5–19.
  13. Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. *Schizophr Res Treatment*. 2012;2012:407171.
  14. Abilify (aripiprazole) [package insert]. Tokyo, Japan: Ostuka Pharmaceutical Co Ltd; 2017.
  15. Invega Sustenna (paliperidone palmitate) extended-release injectable suspension, for intramuscular use [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; 2017.
  16. Risperdal Consta (risperidone) long-acting injection [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; 2016.
  17. Grundmann M, Kacirova I, Urinovska R. Therapeutic drug monitoring of atypical antipsychotic drugs. *Acta Pharm*. 2014;64(4):387–401.
  18. Zyprexa Relprevv (olanzapine) for extended release injectable suspension [package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.
  19. Invega (paliperidone) extended-release tablets [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; 2017.
  20. Invega Trinza (paliperidone palmitate) extended-release injectable suspension, for intramuscular use [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; 2017.
  21. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. *J Clin Psychopharmacol*. 2007;27(1):6–14.
  22. Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. *Schizophr Res*. 2010;116(2–3):107–117.
  23. Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. *JAMA Psychiatry*. 2015;72(8):830–839.
  24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13(2):261–276.
  25. Guy W. *ECDEU Assessment Manual for Psychopharmacology*. Revised Edition. Washington, DC: US Department of Health, Education, and Welfare; 1976.
  26. Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. *N Engl J Med*. 2002;346(1):16–22.
  27. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. *Schizophr Bull*. 1995;21(3):419–429.
  28. Falloon IR, Marshall GN, Boyd JL, et al. Relapse in schizophrenia: a review of the concept and its definitions. *Psychol Med*. 1983;13(3):469–477.
  29. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. *Lancet*. 2012;379(9831):2063–2071.
  30. Mojtabai R, Lavelle J, Gibson PJ, et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. *Psychiatr Serv*. 2002;53(3):337–339.
  31. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. *Schizophr Bull*. 2004;30(2):255–264.
  32. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. *Psychiatr Serv*. 2004;55(8):886–891.
  33. Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry*. 2004;161(2 suppl):1–56.

---

Supplementary material follows this article.

---

You are prohibited from making this PDF publicly available.





THE JOURNAL OF  
**CLINICAL PSYCHIATRY**

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

## **Supplementary Material**

**Article Title:** Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone

**Author(s):** Peter J. Weiden, MD; Edward Kim, MD, MBA; Jason Bermak, MD, PhD; Ibrahim Turkoz, PhD; Srihari Gopal, MD; and Joris Berwaerts, MD

**DOI Number:** 10.4088/JCP.16m11308

### **List of Supplementary Material for the article**

1. [eAppendix 1](#) Paliperidone Dosing Regimens
2. [eTable 1](#) Doses (mg) of ORAL, PP1M, and PP3M Needed to Attain Similar Steady-State Paliperidone Exposure During Maintenance Treatment
3. [eTable 2](#) Comparison of Paliperidone Dose Ranges (mg) in the ORAL, PP1M, and PP3M Studies
4. [eTable 3](#) Paliperidone Dose Regimens in the ORAL, PP1M, and PP3M Studies
5. [eTable 4](#) Inclusion and Exclusion Criteria in the ORAL, PP1M, and PP3M Studies
6. [eTable 5](#) Baseline Demographic and Clinical Characteristics of the Placebo Cohorts (final analysis set) in the Double-Blind Phases of the ORAL, PP1M, and PP3M Studies
7. [eTable 6](#) Baseline Demographics and Disposition of All Patients Who Entered the Double-Blind Phases of the 3 Studies
8. [eTable 7](#) Multiple Cox Proportional Model on Time to Relapse for the Placebo Arms of the ORAL, PP1M, and PP3M Studies (double-blind intent-to-treat populations)
9. [eFigure 1](#) Hazard Function of a Parametric Log-Normal Model on Time to Relapse for the Intent-to-Treat Placebo Double-Blind (DB) Populations From the ORAL, PP1M, and PP3M Studies, With Predictors: Trials, Baseline (DB) Personal and Social Performance Scale, and Prior Hospitalizations for Psychosis

### **Disclaimer**

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

© Copyright 2017 Physicians Postgraduate Press, Inc.

It is illegal to post this copyrighted PDF on any website. ♦ © 2017 Copyright Physicians Postgraduate Press, Inc.

## eAppendix 1

### Paliperidone Dosing Regimens

The paliperidone dosing regimens used in the 3 studies are described in **Supplementary eTable 2**. The daily dose range in the ORAL paliperidone study was 3 mg to 15 mg once daily, and the starting dose was 9 mg once daily. ORAL paliperidone doses of stabilized patients ranged from 9 mg to 15 mg.<sup>21</sup>

Doses of paliperidone palmitate can be expressed both in terms of milligram equivalent (mg eq) of the pharmacologically active fraction, paliperidone, and in milligrams of paliperidone palmitate.<sup>23</sup> Thus, the doses expressed as 25, 50, 75, 100, and 150 mg eq of PP1M equate to 39, 78, 117, 156, and 234 mg, respectively, of PP1M. Similarly, 175, 263, 350, and 525 mg eq of PP3M correspond to 273, 410, 546, and 819 mg of PP3M.<sup>23</sup>

**Supplementary eTable 3** shows doses of ORAL paliperidone, PP1M, and PP3M needed to attain similar steady-state paliperidone exposure during maintenance treatment.<sup>15,23</sup>

In the PP1M study, the PP1M dose range was 39–156 mg and the initial PP1M dose regimen was 78 mg on day 1 and day 8. Most stabilized patients received PP1M 156 mg.<sup>22</sup>

In the PP3M study, the PP1M dose range at the start of the study for most patients was 78 mg to 234 mg and the initial PP1M dose regimen was 234 mg (deltoid) on day 1 and 156 mg (deltoid) on day 8. Most patients received final PP1M doses of 156 mg or 234 mg. When they transitioned from PP1M to PP3M, patients received PP3M at a dose that was 3.5-fold that of the last PP1M dose. Therefore, most patients received a PP3M dose of 546 mg or 819 mg.<sup>23</sup>

**Supplementary eTable 4** shows that the equivalent paliperidone dose ranges evaluated across the 3 studies were somewhat different. Dose ranges were 39 mg to 234 mg in the ORAL paliperidone study, 39 mg to 156 mg in the PP1M study, and 78 mg to 234 mg in the PP3M study. Thus, the range of evaluated doses was lower in the PP1M study than in the PP3M and ORAL paliperidone studies.<sup>15,21-23</sup>

Supplementary eTable 1. Doses (mg) of ORAL, PP1M, and PP3M Needed to Attain Similar Steady-State Paliperidone Exposure During Maintenance Treatment<sup>15,23</sup>

<b>ORAL</b>	<b>PP1M</b>	<b>PP3M</b>
3	39-78	273
6	117	410
9	156	546
12	234	819
15 <sup>a</sup>	NA	NA

NA, not applicable; ORAL, daily extended-release oral paliperidone; PP1M, once-monthly long-acting injectable paliperidone palmitate; PP3M, once-every-3-months long-acting injectable paliperidone palmitate.

<sup>a</sup>Not an approved dose.



Supplementary eTable 2. Comparison of Paliperidone Dose Ranges (mg) in the ORAL, PP1M, and PP3M Studies<sup>15,21,23</sup>

Study 1		Study 2	Study 3
ORAL <sup>a</sup>	Comparable PP1M Dose <sup>a</sup>	PP1M	PP1M Dose Range Before Conversion to PP3M
3	39 or 78	39 or 78	78
6	117	NA	117
9	156	156	156
12	234	NA	234
15 <sup>b</sup>	NA	NA	NA

NA, applicable; ORAL, daily extended-release oral paliperidone; PP1M, once-monthly long-acting injectable paliperidone palmitate; PP3M, once-every-3-months long-acting injectable paliperidone palmitate.

<sup>a</sup>PP1M dose needed to attain similar steady-state paliperidone exposure during maintenance treatment.

<sup>b</sup>Maintenance dose ranges currently approved by the US Food and Drug Administration for patients with schizophrenia are ORAL, 3–12 mg/day;<sup>19</sup> PP1M, 39–234 mg once per month;<sup>15</sup> and PP3M, 273–819 mg once every 3 months.<sup>20</sup>

Supplementary eTable 3. Paliperidone Dose Regimens in the ORAL, PP1M, and PP3M Studies<sup>21-23</sup>

Study Phase	Study		
	ORAL <sup>21</sup>	PP1M <sup>22</sup>	PP3M <sup>23</sup>
Stabilization	<p><i>Regimen:</i> ORAL started at 9 mg once daily and administered at a dose of 3–15 mg once daily</p> <p><i>Results:</i></p> <ul style="list-style-type: none"> <li>45% of patients received 9 mg/day</li> <li>47% of patients had dose increased to 12 or 15 mg dose, 8% were tapered to 6 or 3 mg dose</li> </ul>	<p><i>Regimen:</i> Patients switched from previous antipsychotic and received once-monthly injections of flexibly dosed PP1M (39, 78, or 156 mg) after an initial regimen of PP1M 78 mg on days 1 and 8</p> <p><i>Results:</i> Almost all patients received PP1M 78 mg (53%) or 156 mg (46%) as their final dose</p>	<p><i>Regimen:</i> All patients except those switching from other LAI antipsychotics or those receiving PP1M before study entry received PP1M for 120 days. Doses were: day 1, 234 mg (deltoid); day 8, 156 mg (deltoid); days 36 and 64: 78, 117, 156, or 234 mg flexible doses (deltoid or gluteal)</p> <p><i>Results:</i> Final PP1M doses were 78 mg (2%), 117 mg (8%), 156 mg (48%), and 234 mg (42%)</p>
Maintenance	<p><i>Regimen:</i> Patients were to remain on dose on which they were stabilized</p> <p><i>Results:</i> Doses were 9 mg/day (33%), 12 mg/day (26%), and 15 mg/day (30%)</p>	<p><i>Regimen:</i> Stable patients received flexibly dosed PP1M (39, 78, or 156 mg) for first 12 weeks, with dose adjustments based on clinical need; patients received PP1M treatment at established maintenance dose for 12 weeks</p> <p><i>Results:</i> Final PP1M doses were 39 mg (2%), 78 mg (28%), and 156 mg (69%)</p>	<p><i>Regimen:</i> Patients received a single dose of PP3M in the deltoid or gluteal muscle; dose of PP3M was 3.5-fold that of the final PP1M dose administered on day 92</p> <p><i>Results:</i> PP3M doses were 273 mg (2%), 410 mg (9%), 546 mg (49%), and 819 mg (39%)</p>

LAI, long-acting injectable; ORAL, daily extended-release oral paliperidone; PP1M, once-monthly LAI paliperidone palmitate; PP3M, once-every-3-months LAI paliperidone palmitate.

Supplementary eTable 4. Inclusion and Exclusion Criteria in the ORAL, PP1M, and PP3M Studies<sup>21-23</sup>

Variable	Study		
	ORAL	PP1M	PP3M
<b>Inclusion Criteria</b>			
Male and female	X	X	X
Age 18–65 years	X	X	18–70 years
Diagnosis of schizophrenia <sup>a</sup>	X	X	X
PANSS score (total) <120 at screening and baseline	70–120	X	X
<b>Exclusion Criteria</b>			
DSM-IV diagnosis other than schizophrenia	X	X	X
Significant risk of suicide or aggressive behavior	X	X	X
History of substance dependency <sup>b</sup>	X	X	X
Involuntary admission to a psychiatric hospital	X <sup>c</sup>	X <sup>d</sup>	X <sup>d</sup>
Women pregnant, breastfeeding, or planning pregnancy	X	X	—
Recent use of any 4-week depot antipsychotic prior to screening	X <sup>e</sup>	X <sup>e</sup>	—
Presence of a medical condition that could alter the absorption, metabolism, or excretion of the study medication	X	—	—
Relevant history of significant unstable disease	X	—	—
Known allergic reaction to barbiturates, carbamazepine, lamotrigine, phenytoin, paliperidone, or risperidone	X	—	—
Previous lack of response to risperidone	X	—	—
Exposure to an experimental treatment within 90 days before screening	X	—	—
Electroconvulsive treatment within 3 months before screening	X	—	—
Treatment resistance <sup>f</sup>	—	X	—

Variable	Study		
	ORAL	PP1M	PP3M
Discontinued antiparkinsonian medications, antiepileptics, lithium, $\beta$ -blockers, <sup>g</sup> and monoamine oxidase inhibitors before run-in	X	—	—
Use of risperidone LAI within 5 weeks before screening	—	X	—
Use of oral antipsychotics, mood stabilizers, or OTC drugs within 2 days before baseline	—	X	—
History of neuroleptic malignant syndrome, tardive dyskinesia, or any malignant neoplasm in the previous 5 years <sup>h</sup>	—	—	X

DSM-IV, *Diagnostic and Statistical Manual of Mental Disorders*, fourth edition; LAI, long-acting injectable; ORAL, daily extended-release oral paliperidone; OTC, over-the-counter; PANSS, Positive and Negative Syndrome Scale; PP1M, once-monthly LAI paliperidone palmitate; PP3M, once-every-3-months LAI paliperidone palmitate.

<sup>a</sup>Diagnosis per DSM-IV criteria, for  $\geq 1$  year before screening.

<sup>b</sup>Within 6 months of screening for ORAL and PP3M studies; within 3 months of screening for PP1M study.

<sup>c</sup>At screening.

<sup>d</sup>Any history.

<sup>e</sup>Within 28 days for PP1M study; within 120 days for ORAL study.

<sup>f</sup>Failure to respond to 2 trials; minimum of 4 weeks of antipsychotic medications.

<sup>g</sup>Except if for the treatment of hypertension in stabilized patients.

<sup>h</sup>Except basal cell carcinoma.



Supplementary eTable 5. Baseline Demographic and Clinical Characteristics of the Placebo Cohorts (final analysis set) in the Double-Blind Phases of the ORAL, PP1M, and PP3M Studies<sup>21-23</sup>

Characteristic	ORAL n=101	PP1M n=203	PP3M n=145	P Value <sup>c</sup>
Age, mean±SD, years	37.5±10.4	39.4±10.8	38.5±11.2	0.348
Male, n (%)	63 (62)	111 (55)	110 (76)	<0.001
Race, n (%)				<0.001
White	61 (60)	133 (66)	91 (63)	
Black	9 (9)	36 (18)	21 (14)	
Asian	0	30 (15)	15 (10)	
Other	31 (31)	4 (2)	18 (12)	
BMI, mean±SD, kg/m <sup>2</sup>	26.5±7.9	27.2±6.0 <sup>a</sup>	26.2±4.6	0.290
Age at schizophrenia diagnosis, mean±SD, years	25.8±9.4	28.1±9.1	27.7±9.0	0.116
PANSS total score, mean±SD	53.4±10.6	53.1±11.9	54.2±9.3	0.642
PSP score, mean±SD	72.6±10.4	72.8±10.8	68.6±9.0	<0.001
Previous hospitalizations for psychosis, n (%)				<0.001
0	27 (27)	21 (10)	51 (40) <sup>b</sup>	
1	14 (14)	42 (21)	44 (34) <sup>b</sup>	
≥2	60 (59)	140 (69)	33 (26) <sup>b</sup>	

BMI, body mass index; CGI-S, Clinical Global Impressions–Severity; ORAL, daily extended-release oral paliperidone; PANSS, Positive and Negative Syndrome Scale; PP1M, once-monthly long-acting injectable paliperidone palmitate; PP3M, once-every-3-months long-acting injectable paliperidone palmitate; PSP, Personal and Social Performance scale.

<sup>a</sup>Corresponds to transition baseline BMI calculated using transition baseline weight and height.

<sup>b</sup>Based on n-value of 128.

<sup>c</sup>Comparison of 3 groups.

Supplementary eTable 6. Baseline Demographics and Disposition of All Patients Who Entered the Double-Blind Phases of the 3 Studies

<b>Characteristic</b>	<b>ORAL n=205</b>	<b>PP1M n=408</b>	<b>PP3M n=305</b>	<b>P Value<sup>b</sup></b>
Age (years), mean±SD	38.2±10.5	39.1±11.1	37.8±11.0	0.887
Sex (male), n (%)	121 (59.0)	220 (53.9)	228 (74.8)	<0.001
Race, n (%)				0.447
White	123 (60.0)	266 (65.2)	195 (63.9)	
Other	82 (40.0)	142 (34.8)	110 (36.1)	
Age at schizophrenia diagnosis (years), mean±SD	26.5±9.3	27.3±9.2	26.9±8.6	0.596
Baseline (DB) PANSS score (total), mean±SD	52.2±11.0	52.6±11.8	54.5±9.7	0.022
Baseline (DB) PSP score (total), mean±SD	71.7±10.7	72.4±10.7	68.7±9.1	<0.001
Prior hospitalizations for psychosis, <sup>a</sup> n (%)	n=205	n=408	n=274	<0.001
0	29 (14.2)	88 (21.6)	92 (33.6)	
1	26 (12.7)	86 (21.1)	43 (15.7)	
2	28 (13.7)	67 (16.4)	21 (7.7)	
3	69 (33.7)	124 (30.4)	19 (6.9)	
≥4				

DB, double-blind; PANSS, Positive and Negative Syndrome Scale; ORAL, daily extended-release oral paliperidone; PP1M, once-monthly long-acting injectable paliperidone palmitate; PP3M, once-every-3-months long-acting injectable paliperidone palmitate; PSP, Personal and Social Performance Scale; SD, standard deviation.

<sup>a</sup>For the PP3M cohort, this is the number of hospitalizations within 24 months before the start of the study.

<sup>b</sup>Comparison of 3 groups.


Supplementary eTable 7. Multiple Cox Proportional Model on Time to Relapse for the Placebo Arms of the ORAL, PP1M, and PP3M Studies (double-blind intent-to-treat populations)

<b>Predictors</b>	<b>Maximum Likelihood Estimates</b>			
	<b>Estimate</b>	<b>SE</b>	<b>95% CI</b>	<b>P Value</b>
Baseline (DB) PSP	0.018	0.007	0.003, 0.032	0.016
Trial				<0.001
PP1M vs ORAL	0.808	0.176	0.462, 1.154	<0.001
PP3M vs ORAL	1.322	0.234	0.864, 1.781	<0.001
Prior hospitalizations for psychosis <sup>a</sup>				0.370
1 vs 0	-0.390	0.255	-0.889, 0.110	0.126
2 vs 0	-0.265	0.276	-0.806, 0.276	0.337
3 vs 0	-0.420	0.299	-1.006, 0.165	0.159
≥4 vs 0	-0.505	0.259	-1.013, 0.003	0.051

CI, confidence interval; DB, double-blind; PP1M, once-monthly long-acting injectable paliperidone palmitate; ORAL, daily extended-release oral paliperidone; PP3M, once-every-3-months long-acting injectable paliperidone palmitate; PSP, Personal and Social Performance Scale; SE, standard error.

<sup>a</sup>For the PP3M cohort, this is the number of hospitalizations within 24 months before the start of the study.

Supplementary eFigure 1. Hazard function of a parametric log-normal model\* on time to relapse for the intent-to-treat placebo double-blind (DB) populations from the ORAL, PP1M, and PP3M studies, with predictors: trials, baseline (DB) Personal and Social Performance Scale, and prior hospitalizations for psychosis.



\*The exponential, Weibull, and log-logistic parametric models were also evaluated for model fit, and likelihood-ratio statistics were considered in choosing the log-normal model.

ORAL, daily extended-release oral paliperidone; PP1M, once-monthly long-acting injectable paliperidone palmitate; PP3M, once-every-3-months long-acting injectable paliperidone palmitate.